Cardiovascular Risk in General Practice in France: Cardiovascular Risk Week

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01308372
First received: February 18, 2011
Last updated: November 4, 2011
Last verified: November 2011
  Purpose

The purpose of this study is to evaluate the proportion of patients which present a high cardiovascular risk estimated by the SCORE scale, in general practice consultations of the 7 French regions (Paris area, North-East, Paris basin, West, South-West, South- East, Mediterranean area)


Condition
Healthy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Cardiovascular Risk in General Practice in France

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Evaluation of cardiovascular risk in general practice in France estimated by the SCORE scale [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 2008 scale D'Agostino [ Time Frame: 1 week ] [ Designated as safety issue: No ]
  • Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 1998 scale Wilson [ Time Frame: 1 week ] [ Designated as safety issue: No ]
  • Evaluation of arteries age evaluation by SCORE [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Enrollment: 9246
Study Start Date: October 2011
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
For this group of patients, the cardiovascular risk will be evaluated by several tools: the SCORE scale, the Framingham 2008 scale d'Agostino and the 1998 scale Wilson ;

Detailed Description:

MC MD

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Primary care

Criteria

Inclusion Criteria:

  • Without any personal history of coronary disease
  • Non treated with lipid-lowering agents
  • Lipid test = 1 year old
  • Presenting at least one cardiovascular risk
  • Visiting their General Practitioner

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01308372

  Show 587 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Eric BRUCKERT, Pr. Hôpital Pitié-Salpétrière - Service Endocrinologie-Métabolisme
Principal Investigator: Jean DALLONGEVILLE, Dr. Institut Pasteur de Lille - Unité d'Epidémiologie et de santé publique Inserm UMR 744
Principal Investigator: Jean FERRIERES, Pr. CHU Rangueil - Service de Cardiologie B - Toulouse
Principal Investigator: Serge KOWNATOR, Dr. Thionville -Société Française de Cardiologie
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01308372     History of Changes
Other Study ID Numbers: NIS-CFR-XXX-2011/1
Study First Received: February 18, 2011
Last Updated: November 4, 2011
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
cardiovascular risk
France
General practice
Primary prevention
Non treated patients

ClinicalTrials.gov processed this record on July 29, 2014